Organization | University of Ribeirao Preto

University of Ribeirao Preto Report issue

Academic/Hospital Phase 2 Phase 4

Founded: Ribeirão Preto Brazil (1924)

Organization Overview

First Clinical Trial

2014

NCT01315041

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Faculdade de Medicina de Ribeirão Preto | Faculdade de Medicina de Ribeirão Preto/USP | Hospital das Clinicas de Ribeirao Preto | Hospital das Clínicas de Ribeirão Preto | USP Ribeirão Preto | USP-RP

Active Ingredients

Drugs in Phase 4 Trials (7)

bacille calmette-guerin (1 trial)

bifidobacterium animalis (1 trial)

chickpea (1 trial)

house dust mite allergen (1 trial)

lactobacillus casei (1 trial)

lactobacillus rhamnosus (1 trial)

nifedipine (procardia) (1 trial)

Drugs in Phase 2 Trials (8)

capsicum (1 trial)

cd19 car-t cells (1 trial)

horse chestnut (1 trial)

ipilimumab (yervoy) (1 trial)

maytenus senegalensis (1 trial)

melphalan (alkeran) (1 trial)

nivolumab (opdivo) (1 trial)

omeprazole (prilosec) (1 trial)

Drugs in Other Trials (1)

beetroot juice (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dermatitis (Phase 4)

Dermatitis, Atopic (Phase 4)

Dyspepsia (Phase 2)

Eczema (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 11
# of Trial APIs: 16